There are 2789 resources available
721O - Relacorilant, a selective glucocorticoid receptor modulator, in combination with nab-paclitaxel improves progression-free survival in patients with recurrent platinum-resistant ovarian cancer: A 3-arm, randomized, open-label, phase II study
Presenter: Domenica Lorusso
Session: Proffered Paper session - Gynaecological cancers
Resources:
Abstract
Slides
Webcast
722O - Randomised phase II trial of olaparib compared to weekly paclitaxel or olaparib plus cediranib in patients with platinum-resistant ovarian cancer (OCTOVA)
Presenter: Shibani Nicum
Session: Proffered Paper session - Gynaecological cancers
Resources:
Abstract
Slides
Webcast
LBA33 - Maintenance olaparib rechallenge in patients (pts) with ovarian carcinoma (OC) previously treated with a PARP inhibitor (PARPi): Phase IIIb OReO/ENGOT Ov-38 trial
Presenter: Eric Pujade-Lauraine
Session: Proffered Paper session - Gynaecological cancers
Resources:
Abstract
Slides
Webcast
514O - An open-label, global, first-in-human study of SKB264 in patients with locally advanced or metastatic solid tumors
Presenter: Jordi Rodon
Session: Proffered Paper session - Developmental therapeutics
Resources:
Abstract
Slides
Webcast
LBA27 - Erdafitinib (ERDA) or ERDA plus cetrelimab (CET) for patients with metastatic or locally advanced urothelial carcinoma (mUC) and Fibroblast Growth Factor Receptor alterations (FGFRa): First phase (Ph) II results from the NORSE study
Presenter: Thomas Powles
Session: Proffered Paper session - Genitourinary tumours, non-prostate 1
Resources:
Abstract
Slides
Webcast
651O - Phase II trial of pembrolizumab (P) in combination with sEphB4-HSA (B4) in previously treated metastatic urothelial carcinoma (mUC)
Presenter: Sarmad Sadeghi
Session: Proffered Paper session - Genitourinary tumours, non-prostate 1
Resources:
Abstract
Slides
Webcast
LBA38 - Bexmarilimab, a novel macrophage re-programmer shows promising anti-tumour activity in phase I/II trial in several last line solid tumour types
Presenter: Petri Bono
Session: Proffered Paper session - Investigational immunotherapy
Resources:
Abstract
Slides
Webcast
957O - Long-term follow-up of patients (pts) with human papillomavirus (HPV)–associated malignancies treated with bintrafusp alfa, a bifunctional fusion protein targeting TGF-β and PD-L1
Presenter: James Gulley
Session: Proffered Paper session - Investigational immunotherapy
Resources:
Abstract
Slides
Webcast
958O - Coordinated activation of antitumor responses of g9d2 and CD8 T-cells by targeting BTN3A with ICT01 in patients with solid tumors: EVICTION trial
Presenter: Aurélien Marabelle
Session: Proffered Paper session - Investigational immunotherapy
Resources:
Abstract
Slides
Webcast
959O - Gavocabtagene autoleucel (gavo-cel, TC-210) dose escalation in refractory mesothelin-expressing solid tumors
Presenter: David S. Hong
Session: Proffered Paper session - Investigational immunotherapy
Resources:
Abstract
Slides
Webcast